Rezubio raises RMB 100M+ Series A for its pioneering cell membrane-anchored drug platform targeting chronic diseases

Recently, innovative biopharmaceutical company Rezubio Pharmaceuticals announced the completion of a Series A financing round exceeding RMB 100 million. This round was led by Lapam Capital, with participation from FreeS Fund and Riverhead Capital. ARK Capital acted as the exclusive financial advisor.

Rezubio Pharmaceuticals was founded by a team of former senior scientists from MSD. Its core founders, Dr. Xiong Yusheng and Dr. Guan Hongping, have a history of collaboration on multiple innovative drug development projects. MK-0616 (Enlicitide decanoate), the world's first oral PCSK9 cyclic peptide inhibitor, was spearheaded by Dr. Xiong during his tenure at MSD. The drug has completed several large-scale Phase 3 clinical trials, demonstrating excellent cholesterol-lowering efficacy in patients. The founding team holds multiple global patents and has published several papers in top-tier journals including Science, Nature Medicine, and Cell Metabolism.

Rezubio Pharmaceuticals' proprietary and pioneering "Cell Membrane-Anchored Drug Design Platform" holds promise for systematically addressing the druggability challenges associated with intestinal epithelial cell surface targets, such as G protein-coupled receptors (GPCRs). The first drug candidate derived from this platform is a once-daily oral small molecule targeting metabolic diseases. Currently in Phase I clinical trials in Australia, it is advancing rapidly toward subsequent clinical development phases.

The company's second program, targeting a multi-billion-dollar inflammatory disease market, is in the preparation stage for Investigational New Drug (IND) application submission. Preclinical data support its potential as a best-in-class candidate. Additional pipeline assets, exploring various molecular modalities and delivery methods based on this innovative platform for different indications, are in continuous development.